Avelumab for Merkel Cell Carcinoma

"This trial is no longer recruiting participants; the first posting was July 3rd 2014 and the most recent update being April 21st 2022. If you are searching for a different study, there are 2474 clinical trials actively enrolling patients with carcinoma or Merkel cell cancer as well as 112 studies utilizing Avelumab that need volunteers."

"At present, 112 trials are being conducted to assess the effectiveness of Avelumab. Of these studies, 10 have progressed into Phase 3 and are taking place in Barcelona and South dakota. Additionally there are numerous other locations participating with this research effort at a total of 3685 sites across the world."

"The primary aim of this extensive study, which is projected to last up to 161 weeks, will be the evaluation of Best Overall Response (BOR) as per RECIST 1.1 in participants. Secondary objectives include establishing Minimum Serum Post-dose Concentration of Aveluamb, analysing Overall Survival Time with the Kaplan-Meier method, and determining participant's response status according to RECIST 1.1 at 6 and 12 months. CR: Elimination of all manifestations of target and non-target lesions; PR: Reduction by no less than 30% from baseline in sum diameter length for all lesions are used as qualifying parameters"

"According to clinicaltrials.gov, this medical trial is not currently open for recruitment as it was last updated on April 21st 2022 after being posted in July 2014. However, along with other 2586 active studies there are still plenty of opportunities for potential participants to get involved today."

"Avelumab's safety has been assessed as a 2 because this is an ongoing Phase 2 trial and there are some reports on its safety but none regarding its efficacy."

"Avelumab first entered clinical research in 2014, with its sponsor being EMD Serono Research & Development Institute, Inc. After the success of its Phase 1 trial involving 204 participants, this drug was granted approval for further development. Currently there are 112 active studies running across 1024 cities and 52 countries that make use of Avelumab to treat a variety of medical conditions."

"Currently, 14 clinical sites are administering this trial. These locations include Tampa, Boston and Aurora as well as 11 others - it is beneficial for patients to pick the nearest site in order to limit travel expenses."